MAGNIFY: A phase IIIb trial shows promising efficacy in the treatment of relapsed/refractory, indolent non-Hodgkin lymphoma patients with lenalidomide in combination with rituximab (R2)

被引：0

作者：

Burchardt, A. ^{[1
]}

Andorsky, D. J. ^{[2
]}

Schmidt, B. ^{[3
]}

La Rosee, P. ^{[4
]}

Graeven, U. ^{[5
]}

Czuczman, M. ^{[6
]}

Llorente, M. ^{[6
]}

Li, J. ^{[6
]}

Sharman, J. ^{[7
]}

机构：

[1] Justus Liebig Univ Giessen, Giessen, Germany

[2] US Oncol Res, Rocky Mt Canc Ctr, Boulder, CO USA

[3] Hamatoonkol Uberortliche Gemeinschaftspraxis Pasi, Munich, Germany

[4] Schwarzwald Baar Klinikum, Klin Innere Med 2, Villingen Schwenningen, Germany

[5] Kliniken Maria Hilf GmbH, Klin Hamatol Onkol & Gastroenterol, Monchengladbach, Germany

[6] Celgene Corp, Summit, NJ USA

[7] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V608

引用

页码：160 / 161

页数：2